8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Overview of pharmacovigilance practices at the largest academic healthcare system in the State of Qatar.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Adverse Drug Reactions (ADRs) are major global concern, adversely impacting patient safety and health outcomes. ADRs cause significant morbidity and mortality among hospitalised patients, causing greater length of hospital stay, increased healthcare costs and patient dissatisfaction to the treatments. Pharmacovigilance (PV), a process of detecting, monitoring and preventing drug-related harm, plays a vital role to ensure patient safety. ADR reporting is the cornerstone of PV. PV practices in Qatar are relatively new and are evolving rapidly. The purpose of this article is to explore the medication safety practices (notably ADR reporting) at the largest academic healthcare center in Qatar. The article further provides evidence on how information related to ADRs are generated and interpreted. Furthermore, it describes how a designated center for monitoring medication safety activities was established at the largest healthcare provider in Qatar.

          Related collections

          Author and article information

          Journal
          Int J Clin Pharm
          International journal of clinical pharmacy
          Springer Science and Business Media LLC
          2210-7711
          Aug 2018
          : 40
          : 4
          Affiliations
          [1 ] Hamad Medical Corporation, 3050, Doha, Qatar.
          [2 ] Robert Gordon University, Aberdeen, UK.
          [3 ] Hamad Medical Corporation, 3050, Doha, Qatar. BThomas28@hamad.qa.
          [4 ] Robert Gordon University, Aberdeen, UK. BThomas28@hamad.qa.
          Article
          10.1007/s11096-018-0629-5
          10.1007/s11096-018-0629-5
          29616393
          365ad446-7052-4fa0-b3d4-dd4e2e1425fd
          History

          Adverse Drug Reactions,Hamad Medical Corporation,Medication safety,Pharmacovigilance,Qatar

          Comments

          Comment on this article